Evidence-based Chinese medicine promotes clinical research capacity for emerging infectious diseases_Chinese Journal of Evidence-Based Medicine

Authors：

ZHANG Xinyi ¹ , ZHAO Mengzhu ¹ , LIN Hongyuan ² , YOU Liangzhen ¹ , GUAN Zhiyue ¹ , XU Qianqian ¹ ,  ZHAO Chen ³ ,  SHANG Hongcai ¹

1. Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, P. R. China;
2. College of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha 410208, P. R. China;
3. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, P. R. China;

Corresponding author：

ZHAO Chen, Email: zyyzc2007@163.com; SHANG Hongcai, Email: shanghongcai@126.com

Keywords：

Chinese medicine; Clinical research capacity; COVID-19; Evidence-based medicine

DOI：

10.7507/1672-2531.202302130

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Evidence-based research in traditional Chinese medicine (TCM) has made many important achievements and promoted the modernization and internationalization of TCM. The ability to produce research evidence to guide clinical practice in an emergency treatment situation is a major test of the development of evidence-based Chinese medicine (EBCM) when emerging infectious diseases outbreaks. Along with the development of EBCM, TCM has experienced emerging infectious disease events such as atypical pneumonia (SARS), influenza A (HIN1), and corona virus disease 2019 (COVID-19), and the ability of TCM to conduct clinical research in emergency treatment work has been continuously improved. This article provides an overview of the clinical research conducted in TCM to resist emerging infectious diseases in the past, focusing on the clinical research results obtained in the present time of COVID-19 rescue and treatment, and discusses the role of EBCM development to enhance the clinical research capacity of TCM in emerging infectious diseases.

Citation： ZHANG Xinyi, ZHAO Mengzhu, LIN Hongyuan, YOU Liangzhen, GUAN Zhiyue, XU Qianqian, ZHAO Chen, SHANG Hongcai. Evidence-based Chinese medicine promotes clinical research capacity for emerging infectious diseases. Chinese Journal of Evidence-Based Medicine, 2023, 23(5): 610-615. doi: 10.7507/1672-2531.202302130 Copy

1.	陈可冀, 钱振淮, 张问渠, 等. 精制冠心片双盲法治疗冠心病心绞痛112例疗效分析. 中华心血管病杂志, 1982, 10(2): 85-89.
2.	张俊华, 李幼平, 张伯礼. 循证中医药学: 理论与实践. 中国中药杂志, 2018, 43(1): 1-7.
3.	Tian G, Zhao C, Zhang X, et al. Evidence-based traditional Chinese medicine research: two decades of development, its impact, and breakthrough. J Evid Based Med, 2021, 14(1): 65-74.
4.	王小钦. 正确认识循证医学. 老年医学与保健, 2022, 28(2): 221-223.
5.	Song Y, Yao C, Yao Y, et al. Xuebijing injection versus placebo for critically ill patients with severe community-acquired pneumonia: a randomized controlled trial. Crit Care Med, 2019, 47(9): e735-e743.
6.	Liu Z, Liu Y, Xu H, et al. Effect of electroacupuncture on urinary leakage among women with stress urinary incontinence: a randomized clinical trial. JAMA, 2017, 317(24): 2493-2501.
7.	Xu S, Yu L, Luo X, et al. Manual acupuncture versus sham acupuncture and usual care for prophylaxis of episodic migraine without aura: multicentre, randomised clinical trial. BMJ, 2020, 368: m697.
8.	张俊华, 孙鑫, 李幼平, 等. 循证中医药学的现在和未来. 中国循证医学杂志, 2019, 19(5): 515-520.
9.	中共中央国务院印发《关于促进中医药传承创新发展的意见》. 中医健康养生, 2019, 5(12): 2.
10.	王众楷, 张白玉, 贾善群, 等. 2008~2020年中国法定传染病的流行趋势分析. 郑州大学学报(医学版), 2022, 57(3): 350-356.
11.	潘俊辉, 杨辉, 喻清和, 等. 71例SARS患者中医药介入治疗的临床研究. 中国中西医结合急救杂志, 2003, 10(4): 204-207.
12.	张巍岚, 王相东, 王郁金, 等. 从国医大师邓铁涛治“非典”经验探讨新型冠状病毒肺炎中医诊疗思路. 中医学报, 2020, 35(3): 483-486.
13.	International expert meeting on the treatment of SARS by traditional Chinese medicine ATIO. SARS: clinical trials on treatment using a combination of traditional Chinese medicine and Western medicine: report of the WHO international expert meeting to review and analyses clinical reports on combination treatment for SARS. Geneva: World Health Organization, 2004.
14.	Wang C, Cao B, Liu QQ, et al. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med, 2011, 155(4): 217-225.
15.	Duan ZP, Jia ZH, Zhang J, et al. Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. Chin Med J (Engl), 2011, 124(18): 2925-2933.
16.	戴二黑, 刁士琦, 张洪森, 等. 喜炎平注射液治疗2009年甲型H1N1流感回顾性研究. 上海: 中华中医药学会儿科分会第二十七届全国中医儿科学术研讨会暨世界中医药学会联合会第二届中医儿科国际学术交流大会、中医儿科学理论与实践进展学习班, 2010.
17.	王永炎. 中医药防控新型流感作用与体系建设. 北京: 人民卫生出版社, 2015.
18.	商洪才, 张俊华, 戴国华, 等. 中药大规模临床试验及其管理与质量控制. 中西医结合学报, 2007, 5(1): 1-4.
19.	商洪才, 李幼平, 张伯礼. 中医药临床疗效评价实践中的几点思考. 天津中医药, 2007, 24(4): 275-277.
20.	戴国华, 张伯礼, 郭治昕, 等. 多中心临床试验的研究者培训. 中国新药杂志, 2007, 16(11): 825-828.
21.	戴国华, 张伯礼, 郭治昕, 等. 大样本多中心临床试验协作单位的选择. 中国临床药理学与治疗学, 2006, (6): 717-720.
22.	张俊华, 戴国华, 商洪才, 等. 中医药大规模临床研究的数据核查. 中国循证医学杂志, 2007, 7(3): 230-232.
23.	张俊华, 商洪才, 戴国华, 等. 实现中医药大规模临床研究的动态管理. 中国中医药信息杂志, 2007, (6): 104, 108.
24.	薛素琴, 何羿婷, 卢传坚, 等. 甲型H1N1流感中医药治疗临床研究的质量管理. 重庆医学, 2011, 40(33): 3249-3250.
25.	戴国华, 张伯礼, 郭治昕, 等. 中心随机化系统在“芪参益气滴丸对心肌梗死二级预防的临床试验研究”项目中的应用. 中国中西医结合杂志, 2007, (7): 653-656.
26.	中国临床试验注册中心公告. 中国循证医学杂志, 2007, 7(8): 557-558.
27.	吴泰相, 李幼平, 卞兆祥, 等. 中医药临床随机对照试验报告规范(征求意见稿). 中国循证医学杂志, 2007, 7(8): 601-605.
28.	刘建平. 循证中医药临床研究方法. 北京: 人民卫生出版社, 2009.
29.	刘云涛, 王进忠, 郑丹文, 等. 《新型冠状病毒肺炎诊疗方案(试行第九版)》中医药部分更新解读. 广东医学, 2022, 43(6): 661-663.
30.	李晓东, 刘保延, 王辉, 等. 从治未病谈"武昌模式"在突发性急性传染病防控中的意义. 南京中医药大学学报, 2021, 37(1): 1-5.
31.	黄明, 杨丰文, 郑文科, 等. 中医药治疗新型冠状病毒肺炎方舱医院的建立与成效. 天津中医药, 2022, 39(6): 684-687.
32.	何清, 旷吉琳, 陶孟瑶, 等. 新冠肺炎中国临床研究注册现状分析与思考. 中药与临床, 2020, 11(5): 1-4,33.
33.	WHO. WHO Expert meeting on evaluation of Traditional Chinese Medicine in the treatment of COVID-19. 2022-05-01.
34.	张晓雨, 赵晨, 孙杨, 等. 推动建立临床试验协作与共享机制—疫情蔓延期的战略思考. 中医杂志, 2020, 61(8): 650-654.
35.	邱洪全. 多元协同视角下应急科研协同创新机制与动态评价—以重大疫情为例. 科技管理研究, 2021, 41(2): 38-44.
36.	Gong X, Yuan B, Yuan Y, et al. Efficacy and safety of lianhuaqingwen capsules for the prevention of coronavirus disease 2019: a prospective open-label controlled trial. Evid Based Complement Alternat Med, 2021, 2021: 7962630.
37.	An X, Peng B, Huang X, et al. Ludangshen oral liquid for treatment of convalescent COVID-19 patients: a randomized, double-blind, placebo-controlled multicenter trial. Chin Med, 2022, 17(1): 42.
38.	史锁芳, 方祝元, 熊侃, 等. 扶土生金康复方治疗COVID-19恢复期肺脾不足证患者临床观察. 南京中医药大学学报, 2020, 36(3): 281-285.
39.	杨宏志, 林瑞超, 董汛, 等. 香藿喷雾剂联合基础康复疗法治疗新型冠状病毒肺炎恢复期余毒未清证60例临床研究. 中医杂志, 2021, 62(17): 1509-1513.
40.	史锁芳, 方祝元, 熊侃, 等. 中医综合疗法治疗新型冠状病毒肺炎恢复期气阴两虚证30例临床研究. 江苏中医药, 2021, 53(1): 25-28.
41.	王辉, 金鑫瑶, 庞博, 等. 中医药干预新型冠状病毒肺炎临床研究方案分析. 中国中药杂志, 2020, 45(6): 1232-1241.
42.	李少红, 王玉光, 何丽云, 等. 新型冠状病毒肺炎注册临床试验分析及存在的问题与建议. 中医杂志, 2020, 61(23): 2025-2030.
43.	Qiu R, Zhao C, Liang T, et al. Core outcome set for clinical trials of COVID-19 based on traditional Chinese and Western medicine. Front Pharmacol, 2020, 11: 781.
44.	王月, 陈立, 郑玲, 等. 清肺排毒汤联合常规治疗对新冠肺炎患者的临床疗效. 中成药, 2021, 43(3): 656-659.
45.	Wang JB, Wang ZX, Jing J, et al. Exploring an integrative therapy for treating COVID-19: a randomized controlled trial. Chin J Integr Med, 2020, 26(9): 648-655.
46.	Luo Z, Chen W, Xiang M, et al. The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: a prospective randomized controlled trial. Eur J Integr Med, 2021, 42: 101305.
47.	曾宪红, 马文辉, 王洁. 清肺排毒汤对痰热壅肺型新冠肺炎患者临床疗效的影响. 西部医学, 2020, 32(12): 1799-1801,1806.
48.	李逸雯, 刘玥, 吕诚, 等. 新型冠状病毒肺炎的中医药临床研究: 基于文献计量学分析的解读与思考. 科学通报, 2021, 66(26): 3385-3394.
49.	Wang Y, Lu C, Li H, et al. efficacy and safety assessment of severe covid-19 patients with chinese medicine: a retrospective case series study at early stage of the COVID-19 epidemic in Wuhan, China. J Ethnopharmacol, 2021, 277: 113888.
50.	Zhao C, Li L, Yang W, et al. Chinese medicine formula huashibaidu granule early treatment for mild COVID-19 patients: an unblinded, cluster-randomized clinical trial. Front Med (Lausanne), 2021, 8: 696976.
51.	Liu J, Yang W, Liu Y, et al. Combination of Hua Shi Bai Du granule (Q-14) and standard care in the treatment of patients with coronavirus disease 2019 (COVID-19): a single-center, open-label, randomized controlled trial. Phytomedicine, 2021, 91: 153671.
52.	国家药监局, 国家卫生健康委. 关于发布药物临床试验质量管理规范的公告. 中华人民共和国国务院公报, 2020, (19): 65-86.
53.	国家卫生和计划生育委员会. 涉及人的生物医学研究伦理审查办法. 中华人民共和国国务院公报, 2017, (27): 44-50.
54.	谢洋, 张彭, 赵虎雷, 等. 国际临床试验注册平台注册的新型冠状病毒肺炎临床研究特点分析. 中医杂志, 2020, 61(15): 1294-1298.
55.	胡嘉元, 赵晨, 田然, 等. 中医药临床研究报告规范体系研究. 中国循证医学杂志, 2018, 18(11): 1151-1157.
56.	Cheng CW, Wu TX, Shang HC, et al. CONSORT extension for Chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration. Ann Intern Med, 2017, 167(2): 112-121.
57.	MacPherson H, Altman DG, Hammerschlag R, et al. Revised standards for reporting interventions in clinical trials of acupuncture (STRICTA): extending the CONSORT statement. J Evid Based Med, 2010, 3(3): 140-155.
58.	Fu SF, Cheng CW, Zhang L, et al. Consensus-based recommendations for case report in Chinese medicine (CARC). Chin J Integr Med, 2016, 22(1): 73-79.
59.	刘迈兰, 刘密, 钟欢, 等. 新型冠状病毒肺炎密切接触隔离人员灸法干预的意义与运行模式研究. 中国针灸, 2020, 40(5): 457-461,471.
60.	凌丽, 吕祥, 孙永宁, 等. 新型冠状病毒肺炎疫情防控常态化下中医药临床研究实践与管理的思考. 上海中医药杂志, 2022, 56(10): 4-7.
61.	尹永亮, 陈勇, 许梓妮, 等. 新冠肺炎疫情下信息化助力抗肿瘤药物临床试验质量保证. 肿瘤药学, 2020, 10(S1): 37-41.

1. 陈可冀, 钱振淮, 张问渠, 等. 精制冠心片双盲法治疗冠心病心绞痛112例疗效分析. 中华心血管病杂志, 1982, 10(2): 85-89.
2. 张俊华, 李幼平, 张伯礼. 循证中医药学: 理论与实践. 中国中药杂志, 2018, 43(1): 1-7.
3. Tian G, Zhao C, Zhang X, et al. Evidence-based traditional Chinese medicine research: two decades of development, its impact, and breakthrough. J Evid Based Med, 2021, 14(1): 65-74.
4. 王小钦. 正确认识循证医学. 老年医学与保健, 2022, 28(2): 221-223.
5. Song Y, Yao C, Yao Y, et al. Xuebijing injection versus placebo for critically ill patients with severe community-acquired pneumonia: a randomized controlled trial. Crit Care Med, 2019, 47(9): e735-e743.
6. Liu Z, Liu Y, Xu H, et al. Effect of electroacupuncture on urinary leakage among women with stress urinary incontinence: a randomized clinical trial. JAMA, 2017, 317(24): 2493-2501.
7. Xu S, Yu L, Luo X, et al. Manual acupuncture versus sham acupuncture and usual care for prophylaxis of episodic migraine without aura: multicentre, randomised clinical trial. BMJ, 2020, 368: m697.
8. 张俊华, 孙鑫, 李幼平, 等. 循证中医药学的现在和未来. 中国循证医学杂志, 2019, 19(5): 515-520.
9. 中共中央国务院印发《关于促进中医药传承创新发展的意见》. 中医健康养生, 2019, 5(12): 2.
10. 王众楷, 张白玉, 贾善群, 等. 2008~2020年中国法定传染病的流行趋势分析. 郑州大学学报(医学版), 2022, 57(3): 350-356.
11. 潘俊辉, 杨辉, 喻清和, 等. 71例SARS患者中医药介入治疗的临床研究. 中国中西医结合急救杂志, 2003, 10(4): 204-207.
12. 张巍岚, 王相东, 王郁金, 等. 从国医大师邓铁涛治“非典”经验探讨新型冠状病毒肺炎中医诊疗思路. 中医学报, 2020, 35(3): 483-486.
13. International expert meeting on the treatment of SARS by traditional Chinese medicine ATIO. SARS: clinical trials on treatment using a combination of traditional Chinese medicine and Western medicine: report of the WHO international expert meeting to review and analyses clinical reports on combination treatment for SARS. Geneva: World Health Organization, 2004.
14. Wang C, Cao B, Liu QQ, et al. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med, 2011, 155(4): 217-225.
15. Duan ZP, Jia ZH, Zhang J, et al. Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. Chin Med J (Engl), 2011, 124(18): 2925-2933.
16. 戴二黑, 刁士琦, 张洪森, 等. 喜炎平注射液治疗2009年甲型H1N1流感回顾性研究. 上海: 中华中医药学会儿科分会第二十七届全国中医儿科学术研讨会暨世界中医药学会联合会第二届中医儿科国际学术交流大会、中医儿科学理论与实践进展学习班, 2010.
17. 王永炎. 中医药防控新型流感作用与体系建设. 北京: 人民卫生出版社, 2015.
18. 商洪才, 张俊华, 戴国华, 等. 中药大规模临床试验及其管理与质量控制. 中西医结合学报, 2007, 5(1): 1-4.
19. 商洪才, 李幼平, 张伯礼. 中医药临床疗效评价实践中的几点思考. 天津中医药, 2007, 24(4): 275-277.
20. 戴国华, 张伯礼, 郭治昕, 等. 多中心临床试验的研究者培训. 中国新药杂志, 2007, 16(11): 825-828.
21. 戴国华, 张伯礼, 郭治昕, 等. 大样本多中心临床试验协作单位的选择. 中国临床药理学与治疗学, 2006, (6): 717-720.
22. 张俊华, 戴国华, 商洪才, 等. 中医药大规模临床研究的数据核查. 中国循证医学杂志, 2007, 7(3): 230-232.
23. 张俊华, 商洪才, 戴国华, 等. 实现中医药大规模临床研究的动态管理. 中国中医药信息杂志, 2007, (6): 104, 108.
24. 薛素琴, 何羿婷, 卢传坚, 等. 甲型H1N1流感中医药治疗临床研究的质量管理. 重庆医学, 2011, 40(33): 3249-3250.
25. 戴国华, 张伯礼, 郭治昕, 等. 中心随机化系统在“芪参益气滴丸对心肌梗死二级预防的临床试验研究”项目中的应用. 中国中西医结合杂志, 2007, (7): 653-656.
26. 中国临床试验注册中心公告. 中国循证医学杂志, 2007, 7(8): 557-558.
27. 吴泰相, 李幼平, 卞兆祥, 等. 中医药临床随机对照试验报告规范(征求意见稿). 中国循证医学杂志, 2007, 7(8): 601-605.
28. 刘建平. 循证中医药临床研究方法. 北京: 人民卫生出版社, 2009.
29. 刘云涛, 王进忠, 郑丹文, 等. 《新型冠状病毒肺炎诊疗方案(试行第九版)》中医药部分更新解读. 广东医学, 2022, 43(6): 661-663.
30. 李晓东, 刘保延, 王辉, 等. 从治未病谈"武昌模式"在突发性急性传染病防控中的意义. 南京中医药大学学报, 2021, 37(1): 1-5.
31. 黄明, 杨丰文, 郑文科, 等. 中医药治疗新型冠状病毒肺炎方舱医院的建立与成效. 天津中医药, 2022, 39(6): 684-687.
32. 何清, 旷吉琳, 陶孟瑶, 等. 新冠肺炎中国临床研究注册现状分析与思考. 中药与临床, 2020, 11(5): 1-4,33.
33. WHO. WHO Expert meeting on evaluation of Traditional Chinese Medicine in the treatment of COVID-19. 2022-05-01.
34. 张晓雨, 赵晨, 孙杨, 等. 推动建立临床试验协作与共享机制—疫情蔓延期的战略思考. 中医杂志, 2020, 61(8): 650-654.
35. 邱洪全. 多元协同视角下应急科研协同创新机制与动态评价—以重大疫情为例. 科技管理研究, 2021, 41(2): 38-44.
36. Gong X, Yuan B, Yuan Y, et al. Efficacy and safety of lianhuaqingwen capsules for the prevention of coronavirus disease 2019: a prospective open-label controlled trial. Evid Based Complement Alternat Med, 2021, 2021: 7962630.
37. An X, Peng B, Huang X, et al. Ludangshen oral liquid for treatment of convalescent COVID-19 patients: a randomized, double-blind, placebo-controlled multicenter trial. Chin Med, 2022, 17(1): 42.
38. 史锁芳, 方祝元, 熊侃, 等. 扶土生金康复方治疗COVID-19恢复期肺脾不足证患者临床观察. 南京中医药大学学报, 2020, 36(3): 281-285.
39. 杨宏志, 林瑞超, 董汛, 等. 香藿喷雾剂联合基础康复疗法治疗新型冠状病毒肺炎恢复期余毒未清证60例临床研究. 中医杂志, 2021, 62(17): 1509-1513.
40. 史锁芳, 方祝元, 熊侃, 等. 中医综合疗法治疗新型冠状病毒肺炎恢复期气阴两虚证30例临床研究. 江苏中医药, 2021, 53(1): 25-28.
41. 王辉, 金鑫瑶, 庞博, 等. 中医药干预新型冠状病毒肺炎临床研究方案分析. 中国中药杂志, 2020, 45(6): 1232-1241.
42. 李少红, 王玉光, 何丽云, 等. 新型冠状病毒肺炎注册临床试验分析及存在的问题与建议. 中医杂志, 2020, 61(23): 2025-2030.
43. Qiu R, Zhao C, Liang T, et al. Core outcome set for clinical trials of COVID-19 based on traditional Chinese and Western medicine. Front Pharmacol, 2020, 11: 781.
44. 王月, 陈立, 郑玲, 等. 清肺排毒汤联合常规治疗对新冠肺炎患者的临床疗效. 中成药, 2021, 43(3): 656-659.
45. Wang JB, Wang ZX, Jing J, et al. Exploring an integrative therapy for treating COVID-19: a randomized controlled trial. Chin J Integr Med, 2020, 26(9): 648-655.
46. Luo Z, Chen W, Xiang M, et al. The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: a prospective randomized controlled trial. Eur J Integr Med, 2021, 42: 101305.
47. 曾宪红, 马文辉, 王洁. 清肺排毒汤对痰热壅肺型新冠肺炎患者临床疗效的影响. 西部医学, 2020, 32(12): 1799-1801,1806.
48. 李逸雯, 刘玥, 吕诚, 等. 新型冠状病毒肺炎的中医药临床研究: 基于文献计量学分析的解读与思考. 科学通报, 2021, 66(26): 3385-3394.
49. Wang Y, Lu C, Li H, et al. efficacy and safety assessment of severe covid-19 patients with chinese medicine: a retrospective case series study at early stage of the COVID-19 epidemic in Wuhan, China. J Ethnopharmacol, 2021, 277: 113888.
50. Zhao C, Li L, Yang W, et al. Chinese medicine formula huashibaidu granule early treatment for mild COVID-19 patients: an unblinded, cluster-randomized clinical trial. Front Med (Lausanne), 2021, 8: 696976.
51. Liu J, Yang W, Liu Y, et al. Combination of Hua Shi Bai Du granule (Q-14) and standard care in the treatment of patients with coronavirus disease 2019 (COVID-19): a single-center, open-label, randomized controlled trial. Phytomedicine, 2021, 91: 153671.
52. 国家药监局, 国家卫生健康委. 关于发布药物临床试验质量管理规范的公告. 中华人民共和国国务院公报, 2020, (19): 65-86.
53. 国家卫生和计划生育委员会. 涉及人的生物医学研究伦理审查办法. 中华人民共和国国务院公报, 2017, (27): 44-50.
54. 谢洋, 张彭, 赵虎雷, 等. 国际临床试验注册平台注册的新型冠状病毒肺炎临床研究特点分析. 中医杂志, 2020, 61(15): 1294-1298.
55. 胡嘉元, 赵晨, 田然, 等. 中医药临床研究报告规范体系研究. 中国循证医学杂志, 2018, 18(11): 1151-1157.
56. Cheng CW, Wu TX, Shang HC, et al. CONSORT extension for Chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration. Ann Intern Med, 2017, 167(2): 112-121.
57. MacPherson H, Altman DG, Hammerschlag R, et al. Revised standards for reporting interventions in clinical trials of acupuncture (STRICTA): extending the CONSORT statement. J Evid Based Med, 2010, 3(3): 140-155.
58. Fu SF, Cheng CW, Zhang L, et al. Consensus-based recommendations for case report in Chinese medicine (CARC). Chin J Integr Med, 2016, 22(1): 73-79.
59. 刘迈兰, 刘密, 钟欢, 等. 新型冠状病毒肺炎密切接触隔离人员灸法干预的意义与运行模式研究. 中国针灸, 2020, 40(5): 457-461,471.
60. 凌丽, 吕祥, 孙永宁, 等. 新型冠状病毒肺炎疫情防控常态化下中医药临床研究实践与管理的思考. 上海中医药杂志, 2022, 56(10): 4-7.
61. 尹永亮, 陈勇, 许梓妮, 等. 新冠肺炎疫情下信息化助力抗肿瘤药物临床试验质量保证. 肿瘤药学, 2020, 10(S1): 37-41.

Chinese Journal of Evidence-Based Medicine

Evidence-based Chinese medicine promotes clinical research capacity for emerging infectious diseases

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content